GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zim Laboratories Ltd (NSE:ZIMLAB) » Definitions » Capex-to-Revenue

Zim Laboratories (NSE:ZIMLAB) Capex-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Zim Laboratories Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Zim Laboratories's Capital Expenditure for the three months ended in Dec. 2024 was ₹0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was ₹963.30 Mil.

Hence, Zim Laboratories's Capex-to-Revenue for the three months ended in Dec. 2024 was 0.00.


Zim Laboratories Capex-to-Revenue Historical Data

The historical data trend for Zim Laboratories's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zim Laboratories Capex-to-Revenue Chart

Zim Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.02 0.05 0.09 0.21

Zim Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zim Laboratories's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Capex-to-Revenue falls into.


;
;

Zim Laboratories Capex-to-Revenue Calculation

Zim Laboratories's Capex-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-739.232) / 3555.125
=0.21

Zim Laboratories's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 963.303
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zim Laboratories  (NSE:ZIMLAB) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Zim Laboratories Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zim Laboratories's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Zim Laboratories Business Description

Traded in Other Exchanges
Address
Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is a pharmaceutical company. The company is mainly engaged in the manufacturing of formulation drugs and pre-formulation ingredients. Geographically, the group has a business presence in India and other countries, of which key revenue is derived from Outside India. The products offered by the company are Ondansetron, Melatonin, Nicotine, Vitamin D3, and others. The majority of its revenue is derived from the sale of pharmaceutical goods.

Zim Laboratories Headlines

No Headlines